Xarelto approved for DVT treatmentDrug is the first new oral anticoagulant that does not require routine laboratory monitoring. Even when silent, irregular heartbeat can lead to strokePeople with pacemakers experience atrial arrhythmias without knowing it: study CADTH Corner Steps to better warfarin management. Calculators for who should get low-dose ASA wildly divergent Various tools defined from 26% to 78% of same group as candidates for treatment Controversial angioplasty treatment for MS gets support Patients reported improved quality of life in short-term followup Types of plaque pose different dangers for men, women ‘Atherosclerotic process is not necessarily linear,’ researcher says Iliac stent yields positive results in ORION trial 2012 Canadian hypertension guidelines now available New guidelines put greater emphasis on out-of-office blood pressure measurement. Dyslipidemia educational videos Three short online videos highlight key points in 2009 Canadian dyslipidemia guidelines. Eliquis: third new oral anticoagulant in Canada It is the third new oral anticoagulant to reach the Canadian market, joining rivaroxaban and dabigatran etexilate. First Previous 59 60 61 62 63 Next Last
